Changes in S-100 protein serum levels in survivors of out-of-hospital cardiac arrest treated with mild therapeutic hypothermia: a prospective, observational study
Matthias Derwall¹,², Christian Stoppe¹, David Brücken¹, Rolf Rossaint¹ and Michael Fries¹

¹Department of Anaesthesiology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
²Institute of Neuropathology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany

Corresponding author: Matthias Derwall, mderwall@ukaachen.de

Critical Care 2009, 13:R58 (doi:10.1186/cc7785)
This article is online at: http://ccforum.com/content/13/2/R58
© 2009 Derwall et al.; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract
Introduction Knowledge about the influence of current neuroprotective interventions on prognostic markers after survival from cardiac arrest is lacking. This study aimed to investigate the effects of mild therapeutic hypothermia on the release of the astroglial protein S-100 after cardiopulmonary resuscitation (CPR) in survivors of out-of-hospital cardiac arrest.

Methods This was a prospective, observational study performed during a two-year period, involving medical emergency services and five collaborating hospitals at the city of Aachen, Germany. Sixty-eight subjects were enrolled by the emergency physician on duty by taking blood samples after successful attempts at resuscitation with return of spontaneous circulation (ROSC), followed by samples at 6, 12, 24, 72 and 120 hours post ROSC by the appropriate intensive care unit staff. Depending on the decision of the attending physician, subjects were cooled down to 33°C (n = 37) for 24 hours or were held at 37°C (n = 31). Patients were tracked for estimating mortality and gross neurological outcome for 14 days.

Results S-100 levels in patients not receiving mild therapeutic hypothermia (normothermia (NT)) showed equivalent numbers as compared with cooled patients (mild therapeutic hypothermia (MTH)) on baseline (NT = 1.38 μg/l versus MTH = 1.30 μg/l; P = 0.886). S-100 levels on baseline were significantly lower in patients with a good neurological outcome at 14 days after the event in comparison to their peers with adverse outcome (P = 0.014). Although the difference in S-100 levels of MTH patients with adverse or favourable neurological outcome reached statistical significance, it did not in NT patients.

Conclusions Although the predictive power of S-100 levels were best on admission but not at later time points, MTH had no influence on S-100 serum levels in survivors of non-traumatic out-of-hospital cardiac arrest in the particular setting of this investigation.

Introduction Sudden cardiac arrest (SCA) is the leading cause of death in the USA and Europe affecting about 750,000 people annually [1,2]. Because of improved public training of cardiopulmonary resuscitation (CPR) and advances in professional emergency medical response [3], the rate of return of spontaneous circulation (ROSC) has risen in the past decades. However, depending on the duration of the arrest, neurological survival is still a major concern [4]. The application of mild therapeutic hypothermia (MTH) has been demonstrated to significantly reduce neurological damage in survivors of SCA in two randomised controlled trials [5,6].

Clinically, it is desirable to rely on an early and specific marker for final neurological outcome. Protein S-100B is a potential candidate for estimating post hypoxic neuronal damage due to its neuronal specificity and characteristic behaviour in serum depending on the degree of damage to the central nervous system (CNS) [7-16]. Increased serum levels of S-100 also have prognostic value for unfavourable neurological outcomes.
in patients with traumatic brain injury, stroke and cardiac surgery [17-20]. Several studies have investigated its potential role as a prognostic marker in survivors of SCA and found it to be a reliable marker for hypoxic/ischaemic CNS damage [8,11,13,14,21,22]. The progressive implementation of MTH into clinical practice and its proven impact on neurological outcome has raised the question about its influence on serum levels of S-100.

The present study was therefore conducted to elucidate the influence of MTH on S-100 serum levels in survivors of non-traumatic out-of-hospital cardiac arrest.

Materials and methods
During a two-year period from 2005 to 2007, 68 patients (aged over 18 years) suffering from non-traumatic out-of-hospital cardiac arrest were included in this prospective study. Severe pre-existing conditions diagnosed in the past six months including sepsis, stroke, previous CPR and cancer were regarded as exclusion criteria.

CPR was performed in accordance to European Resuscitation Council’s guidelines for advanced life support 2000 [23], which were gradually replaced by the 2005 edition [24] during the investigation period. In general, professional emergency medical technicians were supervised by an emergency physician on scene.

Demographic and CPR-related data were collected at the emergency department immediately after hospital admission and after 6, 12, 24, 72 and 120 hours at the intensive care unit via a web-based data entry system using an Utstein-Style like template, introduced by the German Society of Anaesthesiology and Intensive Care Medicine [25]. Hospital admission and first withdrawal of blood was defined as baseline.

At corresponding time points, information about haemodynamic and metabolic parameters, such as heart rate (HR), mean arterial pressure (MAP) and lactate and glucose levels, as well as the proof of microbiological pathogens and whether catecholamines were used or not, were documented. Data about the time when MTH was started and how long MTH was maintained were also collected. The decision to initiate MTH was solely at the discretion of the attending physician.

At day 14, neurological outcome was assessed using the cerebral performance categories (CPC) by a physician unaware of the study. CPC 1 and 2 were regarded as favourable neurological outcome, whereas CPC 3 to 5 signified adverse outcome [26].

Because all personal data were kept anonymous and no additional blood samples were taken, the local ethics committee approved the study without the requirement to obtain informed consent from each patient.

Patients received standardised intensive care treatment including mechanical ventilation, tight glucose control, infection control and vasopressor treatment to maintain MAP above 65 mmHg. Additional interventions, such as heart catheterisation, were performed if necessary.

If it was decided to cool the patient, no active warming was applied before induction of MTH. Hypothermia was induced via infusion of one to two litres of cold (about 6°C) saline in combination with body surface cooling using bags filled with ice water. To avoid shivering, patients received a continuous intravenous infusion of non-depolarising neuromuscular-blocking drugs such as rocuronium or pancuronium. Although no specific instructions were supplied by the study protocol, the vast majority of patients nevertheless received a combined continuous infusion of either midazolam or propofol and an opioid. Caregivers were advised to cool down patients as fast as possible in the induction period and to aim to achieve a core temperature of 33°C for 24 hours and to rewarm the patient carefully, not exceeding 1°C per hour. Core temperature was measured with an oesophageal temperature probe, and rewarming was usually performed with a convecting heating blanket.

Serum samples for the determination of S-100 protein were taken from the supernatant of blood collected for routine laboratory analyses and stored at -80°C for later analysis. Serum levels were quantified using a commercially available automated system (LIAison, DiaSorin, Dietzenbach, Germany).

To detect influences of MTH on S-100 protein levels at the given time points, patients were grouped into those receiving MTH or normothermia (NT). In a second analysis, this data were evaluated regarding differences in the final CPC scores, that is, favourable vs. adverse neurological outcome, as defined above. Data were analysed using statistical software SPSS 14.0 (SPSS Inc., Chicago, IL, USA). All results are expressed as mean ± standard deviation. To establish differences between groups, analysis of variance was performed and corrected for multiple comparisons (Bonferroni) in the case of continuous variables. To detect changes over time, repeated measures analysis of variance was employed and followed by pairwise t-tests. Categorical data were analysed using chi-squared test. \( P < 0.05 \) was considered to indicate statistical significance.

Results
No differences between patients treated with or without MTH were found with regard to most of the demographic and arrest-related data (Table 1). Patients treated with MTH were significantly more prone to bacterial infection and more often required catecholamines. Nevertheless, these patients also tended to have a higher in-hospital survival rate (MTH = 78.4% vs. NT = 54.8%; \( P = 0.067 \)) accompanied by a slightly more favourable neurological outcome in comparison with the NT
Available online http://ccforum.com/content/13/2/R58

Table 1

| Demographical and clinical variables of patients treated with mild therapeutic hypothermia (MTH) or normothermia (NT) |
|--------------------------------------------------|
| MTH (n = 37) | NT (n = 31) | P |
|-----------------|--------------|---|
| Age, years | 62.6 ± 15.7 | 67.1 ± 14.0 | 0.229 |
| Sex, % male | 64.7 | 74.2 | 0.442 |
| Survival time, hours | 120 ± 42 | 115 ± 24 | 0.914 |
| Survivors, % | 78.4 | 54.8 | 0.067 |
| Good neurological outcome, % | 56.8 | 45.2 | 0.341 |
| Call-response-interval, min:sec | 03:19 ± 02:26 | 03:05 ± 01:57 | 0.660 |
| Total adrenaline, mg | 4.3 ± 3.8 | 3.2 ± 3.8 | 0.286 |
| Total shocks, n | 3.5 ± 2.6 | 3.8 ± 5.7 | 0.760 |
| Arrest witnessed, % | 40.5 | 51.6 | 0.411 |
| Initial rhythm VF, % | 66.7 | 51.6 | 0.220 |
| Cardiac origin of arrest, % | 91.9 | 64.5 | 0.052 |
| Proof of any pathogen, %* | 67.6 | 12.9 | 0.001 |
| Catecholamines at any time, %* | 97.3 | 71.0 | 0.002 |
| Core temperature at BL, °C* | 35.5 | 36.4 | 0.011 |
| Glasgow coma scale at BL | 3 ± 2 | 4 ± 3 | 0.339 |

*Results presented as mean ± standard deviation. * P < 0.05 MTH vs. NT. BL = baseline; VF = ventricular fibrillation.

Patients treated with MTH had significantly lower oesophageal temperatures already at baseline when compared with NT patients (35.5°C vs. 36.4°C; P = 0.011). The target temperature of 34°C was reached within 3.0 ± 2.2 hours after hospital admission and was maintained for 24.8 ± 4.9 hours. Lowest values were recorded 12 hours after baseline, with mean values of 33.4 ± 0.8°C. NT patients developed sub-febrile temperatures with a peak of 37.9°C at 12 hours post resuscitation (Figure 1).

S-100 levels at baseline were significantly elevated in patients with adverse neurological outcome (P = 0.014). This was also true after 24 and 72 hours (Table 2).

There were no significant differences in S-100 serum levels between NT and MTH patients at any time point (Figure 2).

Regardless of neurological outcome, S-100 serum levels were almost congruent from six hours after ROSC in NT patients as depicted in Figure 3. In contrast, patients treated with MTH and a favourable neurological outcome showed a strong trend to lower S-100 serum levels being significant after 24 hours (CPC 1 to 2 = 0.56 vs. CPC 3 to 5 = 0.24; P = 0.001; Figure 4).
In the present study the administration of MTH did not significantly influence serum levels of S-100 protein in patients surviving non-traumatic out-of-hospital cardiac arrest. Both patients treated with or without MTH showed comparable decreases in S-100 serum levels over time (Figure 2). These findings were only marginally different when patients were stratified according to the final neurological outcome.

S-100 protein is an astrocyte-derived neurotrophic protein which is strongly associated with the promotion of neuronal growth and survival [27]. It is predominately found in astro-

Table 2

| Timepoint | Neurological outcome | P value |
|-----------|----------------------|---------|
|           | Good (CPC 1 to 2)    | Bad (CPC 3 to 5) |
| BL*       | 0.81 ± 1.09          | 1.93 ± 1.78 | 0.028 |
| 6 hours   | 0.47 ± 0.45          | 0.71 ± 0.67 | 0.192 |
| 12 hours  | 0.37 ± 0.39          | 0.57 ± 0.53 | 0.166 |
| 24 hours* | 0.27 ± 0.22          | 0.51 ± 0.31 | 0.002 |
| 72 hours* | 0.21 ± 0.15          | 0.41 ± 0.40 | 0.030 |
| 120 hours | 0.17 ± 0.09          | 0.19 ± 0.10 | 0.669 |

Results presented as mean ± standard deviation. *P < 0.05 cerebral performance categories (CPC) 1 to 2 vs. CPC 3 to 5. BL = baseline.

Discussion
In the present study the administration of MTH did not significantly influence serum levels of S-100 protein in patients surviving non-traumatic out-of-hospital cardiac arrest. Both patients treated with or without MTH showed comparable decreases in S-100 serum levels over time (Figure 2). These findings were only marginally different when patients were stratified according to the final neurological outcome.

S-100 protein is an astrocyte-derived neurotrophic protein which is strongly associated with the promotion of neuronal growth and survival [27]. It is predominately found in astro-

Figure 2

Time course of S-100 protein. S-100 protein serum levels in patients receiving mild therapeutic hypothermia (MTH) vs. normothermia (NT). BL = baseline.

Figure 3

S-100 time course – normothermia. S-100 serum levels in patients (n = 31) receiving normothermia (NT) for cerebral performance categories (CPC) 1 to 2 vs. 3 to 5. BL = baseline.

Figure 4

S-100 time course – mild therapeutic hypothermia. S-100 serum levels in patients (n = 37) receiving mild therapeutic hypothermia (MTH). *P < 0.05 for cerebral performance categories (CPC) 1 to 2 vs. 3 to 5. BL = baseline.
cytes and Schwann cells [28] and may play a crucial role in the process of learning and memory [29]. Due to its molecular weight of 21,000 Dalton, S-100B may only be detected in peripheral blood if the integrity of the blood-brain barrier (BBB) is disrupted. On the other hand, a specific lesion to the BBB not involving the CNS may also result in elevated serum levels [30]. Rises in S-100 serum levels are also reported from extracerebral tissues such as marrow, fat or muscle [31]. Despite its obvious lack of specificity, it has nevertheless been found to be an early and sensitive marker of hypoxic brain damage and short-term outcome after cardiac arrest [8,10,11,13-16,19]. Our study is in accordance with these previous reports as at several time points patients with bad neurological outcome had significantly higher serum levels in S-100 protein. Remarkably, the prognostic value of S-100 for neurological outcome in this study diminished over time. Therefore, the initial measurement shortly after admission to the hospital was the most valuable within the post-resuscitation period.

Two previous studies have focused on the effect of therapeutic hypothermia on levels of serum S-100B protein in survivors of cardiac arrest [32,33]. Although Hachimi-Idrissi and colleagues [32] observed a mixed population of patients with asystole and ventricular fibrillation (VF), the study by Tiainen and colleagues [33] only included patients with VF, which did not reveal a significant decline of S-100B values in MTH patients. In contrast, Hachimi-Idrissi and colleagues found a significant decline in MTH patients as compared with NT treatment [32]. The decline was even more pronounced in patients with asystole as initial rhythm. Because patients in our investigation predominantly presented with VF as initial rhythm (66.7% in MTH vs 51.6% in NT) our results seem to support the notion of a connection between initial ECG and the influence of MTH on this surrogate marker.

Although we recognised a trend towards higher survival rates as well as improved neurological outcome, we did not detect significant improvements of these two important endpoints in this investigation which contrasts the findings from previous larger studies. The absolute difference of 11.6% more patients with beneficial neurological outcome and 23.6% higher in-hospital survival rate may nevertheless be seen as a testimony for the potency of this intervention, even in a heterogeneous population. However, it has to be acknowledged that in our study patients with rhythms other than VF were also included, which per se have lower chances of survival after cardiac arrest [5,6].

We recognise several limitations in the interpretation of our study. First, our results may be influenced by the relatively low number of patients with the possibility of a lack of adequate power to detect statistical differences. However, in prospective studies of cardiac arrest, 68 patients represent a relatively large population. An enlargement of the study population is nevertheless almost impossible because of an almost 100% implementation of therapeutic hypothermia in the participating hospitals today. Patients treated with NT will therefore scarcely be available for recruitment.

Second, although S-100 is frequently referred to as a specific surrogate marker for the severity of hypoxic brain injury, there are other circumstances that may also result in elevated serum levels. Recently, two studies suggested that serum levels may also be elevated in children [34] as well as in adults [35] during sepsis or septic shock, indicating a potential role of infection and inflammation in the release of S-100 protein. Due to the high infection rate in patients receiving MTH in our study, this might have had a certain influence on our results.

Third, the observational nature of the study which precluded formal randomisation may have led to a systemic bias in a way that patients with a bad prognosis may have been withdrawn from extensive hypothermic treatment. Some of the patients might have been actively or passively cooled before admission to the hospital which could have directed the in-hospital caregivers in most cases to proceed with this therapy rather than abolishing it. The latter might also be an explanation for the difference in temperature between MTH and NT patients at baseline.

Finally, although at the time of the study all participating hospitals were at the time of the study employing standardised intensive care therapy, such as low tidal volume ventilation, tight glucose control etc., the multiple centre setup can not exclude minor differences in standard intensive care therapy or application of MTH. Although no differences in demographic data were evident, the favourable CPC in the MTH group might be influenced by treating only patients with a good prognosis with MTH, while others received NT. The collected outcome data 14 days after ROSC have to be seen as medium-term related endpoints which might not necessarily reflect long-term results.

**Conclusions**

In recognising these limitations we conclude that in a mixed population of patients with cardiac arrest, MTH had no influence on S-100 serum levels in survivors of non-traumatic out-of-hospital cardiac arrest in the present investigation. The predictive quality of S-100 levels was best on admission but not on later time points during the first five days of hospitalisation.

**Competing interests**

The authors declare that they have no competing interests.
Key messages

- In 68 patients after successful CPR, S-100 levels showed comparable serum levels in patients receiving NT as compared with cooled patients.
- S-100 levels on baseline were significantly lower in patients with a good neurological outcome at 14 days after the event in comparison to their peers with adverse outcome.
- MTH did not significantly influence serum levels of S-100 protein in patients surviving non-traumatic out-of-hospital cardiac arrest in this study.
- The predictive quality of S-100 levels was best on admission but not on later time points.

Authors' contributions

MD performed the statistical analysis and drafted the manuscript. DB and CS carried out the acquisition of investigated materials. RR participated in the design of the study and its coordination. MF conceived of the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Parts of the study were supported by the Laerdal Foundation for Acute Medicine, Stavanger, Norway. The sponsor had no involvement in the study design and coordination. MF conceived of the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

References

1. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care – part 3: overview of CPR. Circulation 2005, 112 (Suppl IV):203.
2. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben LG, Wellens HJ: Out-of-hospital cardiac arrest in the 1990’s: a population-based study in the Maastricht area on incidence, characteristics and survival. Am Coll Cardiol 1997, 30:1500-1505.
3. Becker L, Gold LS, Eisenberg M, White L, Hearne T, Rea T: Ventricular fibrillation in King County, Washington: A 30-year perspective. Resuscitation 2008, 79:22-27.
4. van Alem AP, de Vos R, Schmand B, Koster RW: Cognitive impairment in survivors of out-of-hospital cardiac arrest. Am J Cardiol 2004, 100:416-421.
5. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002, 346:549-556.
6. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Guteridge GM, Smith K: Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002, 346:557-563.
7. Bloomfield SM, McKinney J, Smith L, Brisman J: Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care 2007, 6:121-138.
8. Bottiger BW, Moberg S, Glätzer R, Bauer H, Gries A, Bartsch P, Motsch J, Martin E: Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation 2001, 103:2694-2698.
9. Fries M, Bickenbach J, Beckers S, Hensler D, Rossaint R, Kuhlen R: [Neuromonitoring with S-100 protein in the intensive care unit]. Anaesthesist 2004, 53:959-964.
10. Grubb NR, Simpson C, Sherwood RA, Abraha HD, Cobbe SM, O'Carroll RE, Deary I, Fox KA: Prediction of cognitive dysfunction after resuscitation from out-of-hospital cardiac arrest using serum neuron-specific enolase and protein S-100. Heart 2007, 93:1268-1273.
11. Hachimi-Idrissi S, Auwera M Van der, Schiettecatte J, Ebingar G, Michotte Y, Huigghens L: S-100 protein as early predictor of regaining consciousness after out of hospital cardiac arrest. Resuscitation 2005, 25:251-257.
12. Mussack T, Biberthaler P, Gipper Steppert C, Kanz KG, Wiedemann E, Mutschler W, Jochem M: Early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated severe head trauma: a comparative pilot study on common pathomechanisms. Resuscitation 2001, 49:189-190.
13. Mussack T, Biberthaler P, Kanz KG, Wiedemann E, Gipper Steppert C, Jochem M: S-100b, sE-selecitin, and sP-selectin for evaluation of hypoxic brain damage in patients after glacial cerebral ischemia. Stroke 1998, 29:2383-2386.
14. Pfeifer R, Borner A, Krack A, Sigusch HH, Surber R, Figulla HR: Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron-specific enolase and protein S-100 and the Glasgow Coma Scale. Resuscitation 2005, 65:49-55.
15. Rosen H, Rosengren L, Herlitz J, Blomstrand C: Increased serum levels of the S-100 protein are associated with hypoxic brain damage after cardiac arrest. Stroke 1998, 29:473-477.
16. Rosen H, Sunnerhagen KS, Herlitz J, Blomstrand C, Rosengren L: Serum levels of the brain-derived proteins S-100 andNSE predict long-term outcome after cardiac arrest. Resuscitation 2001, 49:183-191.
17. Elting JW, de Jager AE, Teelken AW, Schauf MJ, Maurits NM, Naakt van der, Sibonga JT, Suffer GA, De Keyser J: Comparison of serum S-100 protein levels following stroke and traumatic brain injury. J Neurol Sci 2000, 181:104-110.
18. Jonsson H, Johnson P, Birch-Lenssen M, Alling C, Westaby S, Blomquist S: S100B as a predictor of size and outcome of stroke after cardiac surgery. Ann Thorac Surg 2001, 71:1433-1437.
19. Martens P, Raabe A, Johnson P: Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after cardiac arrest. N Engl J Med 2000, 346:1500-1505.
20. Missler U, Wissmann M, Friedrich C, Kaps M: S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997, 28:1956-1960.
21. Ekmektzoglou KA, Kastrinos T, Papadimitriou L: Biochemical markers (NSE, S-100, IL-8) as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation. Resuscitation 2007, 75:219-228.
22. Fries M, Kunz D, Gressner AM, Rossaint R, Kuhlen R: Procalcitonin serum levels after out-of-hospital cardiac arrest. Resuscitation 2003, 59:105-109.
23. de Latorre F, Nolan J, Robertson C, Chamberlain D, Baskett P: European Resuscitation Council Guidelines 2000 for Adult Advanced Life Support. A statement from the Advanced Life Support Working Group(1) and approved by the Executive Committee of the European Resuscitation Council. Resuscitation 2001, 48:211-221.
24. Nolan JP, Deakin CD, Soar J, Bottiger BW, Smith G: European Resuscitation Council guidelines for resuscitation 2005. Section 4. Adult advanced life support. Resuscitation 2005, 67(Suppl 1):S39-86.
25. Gräser JT, Messelken M, Fischer M, Riosloaki Jantzen T, Bahr J, Bottiger BW, Dörges V, Franz R, Gries A, Krieter H, Schüttler J, Winnjet J, Zander JF, Scholz J: The DGAi CPR Registry: The Data-sets "Hospital Care" and "11-Long-Term Process", Anaesthesiol Intensivmed Notfallmed Schmerzther. 2008, 43:706-709.
26. Safar P: Resuscitation after brain ischemia. In Brain Failure and Resuscitation Edited by: Grenvik A, Safar P. New York: Churchill Livingstone; 1981:155-184.
27. Barger SW, Van Eldik LJ: S100 beta stimulates calcium fluxes in glial and neuronal cells. J Biol Chem 1992, 267:9689-9694.
28. Donato R: Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999, 1450:181-231.
29. Karpiak SE, Serokosz M, Rapport MM: Effects of antisera to S-100 protein and to synaptic membrane fraction on maze performance and EEG. Brain Res 1976, 102:313-321.

30. Kapural M, Krizanic-Bengez L, Barnett G, Perl J, Masaryk T, Apollo D, Rasmussen P, Mayberg MR, Janigro D: Serum S-100beta as a possible marker of blood-brain barrier disruption. Brain Res 2002, 940:102-104.

31. Anderson RE, Hansson LO, Nilsson O, Liaka J, Settergren G, Vaage J: Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources. Ann Thorac Surg 2001, 71:1512-1517.

32. Hachimi-Idrissi S, Zizi M, Nguyen DN, Schiettecate J, Ebinger G, Michotte Y, Huyghens L: The evolution of serum astroglial S-100 beta protein in patients with cardiac arrest treated with mild hypothermia. Resuscitation 2005, 64:187-192.

33. Tiainen M, Roine RO, Pettia V, Takkunen O: Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia. Stroke 2003, 34:2881-2886.

34. Hsu AA, Fenton K, Weinstein S, Carpenter J, Dalton H, Bell MJ: Neurological injury markers in children with septic shock. Pediatr Crit Care Med 2008, 9:245-251.

35. Nguyen DN, Spapen H, Su F, Schiettecatte J, Shi L, Hachimi-Idrissi S, Huyghens L: Elevated serum levels of S-100beta protein and neuron-specific enolase are associated with brain injury in patients with severe sepsis and septic shock. Crit Care Med 2006, 34:1967-1974.